Peregrine Asset Advisers’s iShares Biotechnology ETF IBB Stock Holding History

Peregrine Asset Advisers’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$555K	Hold	2,916	–	–	0.12%	128
2026 Q1	$492K	Hold	2,916	–	–	0.13%	118
2025 Q4	$492K	Hold	2,916	–	–	0.14%	106
2025 Q3	$421K	Hold	2,916	–	–	0.13%	118
2025 Q2	$369K	Hold	2,916	–	–	0.12%	118
2025 Q1	$373K	Sell	2,916 -5	-0.2%	-$678	0.14%	113
2024 Q4	$386K	Sell	2,921 -546	-16%	-$76.8K	0.14%	107
2024 Q3	$505K	Buy	3,467 +222	+7%	+$32.1K	0.17%	103
2024 Q2	$445K	Hold	3,245	–	–	0.18%	99
2024 Q1	$445K	Hold	3,245	–	–	0.18%	98
2023 Q4	$441K	Hold	3,245	–	–	0.21%	90
2023 Q3	$397K	Buy	+3,245	New	+$413K	0.21%	90
2021 Q1	–	Sell	-24,774	Closed	-$3.75M	–	132
2020 Q4	$3.75M	Buy	+24,774	New	+$3.54M	1.75%	16
2018 Q4	–	Sell	-3,653	Closed	-$445K	–	97
2018 Q3	$445K	Buy	+3,653	New	+$430K	0.2%	72
2018 Q1	–	Sell	-74,780	Closed	-$7.98M	–	105
2017 Q4	$7.98M	Buy	+74,780	New	+$7.99M	3.99%	5
2015 Q3	–	Sell	-1,755	Closed	-$216K	–	99
2015 Q2	$216K	Buy	+1,755	New	+$210K	0.16%	97

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Peregrine Asset Advisers's IBB Position: Q2 2026 in Review

Peregrine Asset Advisers held its iShares Biotechnology ETF (IBB) position steady in Q2 2026 at 2,916 shares worth $555K. The position accounts for 0.12% of the portfolio, ranked #128.

Peregrine Asset Advisers first reported a position in IBB in Q2 2015 and has held it in 16 quarters since. The position peaked at $7.98M in Q4 2017. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Peregrine Asset Advisers held 2,916 shares of iShares Biotechnology ETF worth $555K as of Q2 2026.
Peregrine Asset Advisers left its iShares Biotechnology ETF share count unchanged in Q2 2026.
iShares Biotechnology ETF made up 0.12% of Peregrine Asset Advisers's portfolio in Q2 2026, its #128 holding.
Peregrine Asset Advisers first reported a position in iShares Biotechnology ETF in Q2 2015 and has held it in 16 quarters since.
Peregrine Asset Advisers's iShares Biotechnology ETF position peaked at $7.98M in Q4 2017.
954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Peregrine Asset Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.